An in vivo test to assess mefloquine 25 mg/kg for the treatment of uncomplicated falciparum malaria in Rondônia, Brazil

4Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Drug-resistant Plasmodium falciparum is undermining malaria control efforts worldwide. In Brazil, mefloquine (MQ) at a dose of 15 mg/kg body weight is used to treat P. falciparum. At this dose, MQ resistance developed rapidly in Thailand. Use of a higher MQ dose may retard the development of resistance. We treated 50 patients aged one to 67 years who had acute, uncomplicated P falciparum malaria using MQ 25 mg/kg. There were no serious adverse events. Two patients complained of dizziness and insomnia. Assessing evaluable patients, the day 42 cure rate was 40/42 [95.2% (95% confidence interval 83.8 to 99.4%)]. Mefloquine was efficacious and well tolerated in this small cohort from the state of Rôndonia. © 2006 by The Brazilian Journal of Infectious Diseases and Contexto Publishing. All rights reserved.

Cite

CITATION STYLE

APA

Basano, S. A., Bianco, A., Taylor, W. R. J., Olliaro, P., & Camargo, L. M. A. (2006). An in vivo test to assess mefloquine 25 mg/kg for the treatment of uncomplicated falciparum malaria in Rondônia, Brazil. Brazilian Journal of Infectious Diseases, 10(4), 279–282. https://doi.org/10.1590/S1413-86702006000400013

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free